MSH|^~\&|Reports|CML|||200910060651-500||ORU^R01||1|2.3PID|1|||2222222222^HC^ON|ANDERSON^PAMELA||19670701|F|||||7055852462ORC|NW|ZK59632|||F|||||||290692^DR. NORMAN BETHUNE|||20091001OBR|1|ZK59632||669^CHLAMYDIA||20091001|20091001|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|4600^ SOURCE|RIA^CHLAMYDIA NA-HYBRIDIZATION^|CERVICAL||||||F||465^1004600||70OBX|2|ST|4610^ CHLAMYDIA|RIA^CHLAMYDIA NA-HYBRIDIZATION^|NEGATIVE||||||F||465^1004610||70OBR|2|ZK59632||700^DOCUMENTATION FEE||20091001|20091001|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBR|3|ZK59632||627^GC CULTURE||20091001|20091001|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|62710^SOURCE|^MICROBIOLOGY^CULTURE FOR GC|CERVICAL||||||F||6520^1062710||70OBX|2|ST|62751^STATUS|^MICROBIOLOGY^CULTURE FOR GC|FINAL||||||F||6520^1062751||70OBX|3|ST|62761^CULTURE|^MICROBIOLOGY^CULTURE FOR GC|||||||F||6520^1062761||70NTE|1|L|NO N. GONORRHOEAE ISOLATED AT 48 HOURS.NTE|2|L|  NTE|3|L|IF THE CULTURE BECOMES POSITIVE IN THE NTE|4|L|NEXT 24 HOURS A FURTHER REPORT WILL BE     NTE|5|L|ISSUED.PID|2|||1008614305^MJ^ON|CAREY^JIM||19620117|M|||||7056880561ORC|NW|ZL84625|||F|||||||290692^DR. NORMAN BETHUNE|||20091002OBR|1|ZL84625||111FS^GLUCOSE FASTING-SER||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3007^GLUCOSE FASTING-SER|CHEMISTRY^^|6.9|MMOL/L|3.3-6.0|A|||F||303^1003007||70OBR|2|ZL84625||093^HEMOGLOBIN A1C||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3767^HEMOGLOBIN A1C|CHEMISTRY^^|0.051||0.040-0.060||||F||303^1003767||70OBR|3|ZL84625||341^SENSITIVE TSH||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|4025^TSH|RIA^^|5.34|MU/L|0.30-4.70|A|||F||401^1004025||70OBR|4|ZL84625||067^CREATININE||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3180^CREATININE|CHEMISTRY^^|93|UMOL/L|60-127||||F||303^1003180||70OBX|2|ST|3190^eGFR|CHEMISTRY^^|71||||||F||303^1003190||70NTE|1|L|     ****          ****          ****NTE|2|L|For patients of African descent, the reportedNTE|3|L|eGFR must be multiplied by a correctionNTE|4|L|factor of 1.21.NTE|5|L|     ****          ****          ****OBR|5|ZL84625||226^SODIUM||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3210^SODIUM|CHEMISTRY^^|136|MMOL/L|135-146||||F||303^1003210||70OBR|6|ZL84625||204^POTASSIUM||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3220^POTASSIUM|CHEMISTRY^^|3.9|MMOL/L|3.5-5.2||||F||303^1003220||70OBR|7|ZL84625||223^SGPT (ALT)||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3380^ALT|CHEMISTRY^^|60|U/L|4-43|A|||F||303^1003380||70OBR|8|ZL84625||191^PHOSPHATASE ALKALINE||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3360^ALK PHOS|CHEMISTRY^^|217|U/L|30-110|A|||F||303^1003360||70OBR|9|ZL84625||030^BILRUBIN TOTAL||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3340^TOTAL BILIRUBIN|CHEMISTRY^^|62.0|UMOL/L|0.0-23.0|A|||F||303^1003340||70NTE|1|L|SPECIMEN IS ICTERICOBR|10|ZL84625||005^ALBUMIN QUANT||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3270^ALBUMIN|CHEMISTRY^^|18.4|G/L|33.0-46.0|A|||F||303^1003270||70OBR|11|ZL84625||117^HDL/LDL||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3120^CHOLESTEROL|CHEMISTRY^^|3.03|MMOL/L|TARGET <5.20||||F||365^1003120||70OBX|2|ST|3140^TRIGLYCERIDES|CHEMISTRY^^|1.17|MMOL/L|TARGET <1.71||||F||365^1003140||70OBX|3|ST|3923^HDL CHOLESTEROL|CHEMISTRY^^|0.91|MMOL/L|TARGET >1.29|A|||F||365^1003923||70OBX|4|ST|3933^LDL CHOLESTEROL|CHEMISTRY^^|1.59|MMOL/L|See Targets||||F||365^1003933||70OBX|5|ST|3939^CHOL/HDL RATIO|CHEMISTRY^^|3.33||See Targets||||F||365^1003939||70NTE|1|L|*----------*----------*----------*----------*NTE|2|L|Clinical Risk Status:  Target Lipid LevelsNTE|3|L|*----------*----------*----------*----------*NTE|4|L| If Risk  : LDL-C --Targets-- CHOL/HDL RatioNTE|5|L| Low      :  <5.1     and       <6.0NTE|6|L| Moderate :  <3.5     and       <5.0NTE|7|L| High     :  <2.0     and       <4.0NTE|8|L|...as per 2006 Canadian GuidelinesOBR|12|ZL84625||393^COMPLETE BLOOD COUNT||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|2010^HEMOGLOBIN|HEMATOLOGY^^|138|G/L|135-180||||F||201^1002010||70OBX|2|ST|2013^HEMATOCRIT|HEMATOLOGY^^|0.395|L/L|0.37-0.54||||F||201^1002013||70OBX|3|ST|2016^WBC COUNT|HEMATOLOGY^^|5.6|X10 9/L|4.0-11.0||||F||201^1002016||70OBX|4|ST|2019^RBC COUNT|HEMATOLOGY^^|3.65|X10 12/L|4.50-6.50|A|||F||201^1002019||70OBX|5|ST|2022^MCV|HEMATOLOGY^^|108.2|FL|80-97|A|||F||201^1002022||70OBX|6|ST|2025^MCH|HEMATOLOGY^^|37.8|PG|27.0-32.0|A|||F||201^1002025||70OBX|7|ST|2028^MCHC|HEMATOLOGY^^|349|G/L|320-360||||F||201^1002028||70OBX|8|ST|2029^RDW|HEMATOLOGY^^|19.2|%|11.0-14.5|A|||F||201^1002029||70OBX|9|ST|2030^PLATELET COUNT|HEMATOLOGY^^|45|X10 9/L|150-400|A|||F||201^1002030||70OBX|10|ST|2191^ABSOLUTE:  NEUTROS|HEMATOLOGY^^|2.6|X10 9/L|2.0-7.5||||F||201^1002191||70OBX|11|ST|2193^     (A)   LYMPH|HEMATOLOGY^^|1.7|X10 9/L|1.1-3.3||||F||201^1002193||70OBX|12|ST|2196^     (A)   MONO|HEMATOLOGY^^|0.7|X10 9/L|0.0-0.8||||F||201^1002196||70OBX|13|ST|2197^     (A)   EOS|HEMATOLOGY^^|0.4|X10 9/L|0.0-0.5||||F||201^1002197||70OBX|14|ST|2198^     (A)   BASO|HEMATOLOGY^^|0.1|X10 9/L|0.0-0.2||||F||201^1002198||70OBX|15|ST|2089^MACROCYTOSIS|HEMATOLOGY^^|1+|||A|||F||203^1002089||70OBX|16|ST|2101^TARGET CELLS|HEMATOLOGY^^|1+|||A|||F||203^1002101||70OBX|17|ST|2111^PLATELETS|HEMATOLOGY^^|MKD REDUCED|||A|||F||203^1002111||70OBR|13|ZL84625||445^INR (PT)||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|2.2||0.8-1.2|A|||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|14|ZL84625||005RU^MICROALBUMIN-RANDOM||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3532^MICROALBUMIN (RUR)|CHEMISTRY^^URINE CHEMISTRY:|5.8|MG/L|BELOW 15||||F||313^1003532||70OBR|15|ZL84625||3670^MICROALB:CREAT-RU||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3535^CREATININE (RUR)|CHEMISTRY^^URINE CHEMISTRY:|24.4|MMOL/L|5.0-13.0|A|||F||313^1003535||70OBX|2|ST|3536^MICROALB/CREAT.|CHEMISTRY^^URINE CHEMISTRY:|0.2||< 2.0||||F||313^1003536||70OBR|16|ZL84625||700^DOCUMENTATION FEE||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBR|17|ZL84625||800^BLOOD FILM INTERPRETATION||20091002|20091002|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|2112^BLD FILM EXAM|HEMATOLOGY^^|||||||F||221^1002112||70|^A. SEIDENFELD, M.D.^F.R.C.P.(C)NTE|1|L|MILD MACROCYTOSIS, MARKED THROMBOCYTOPENIANTE|2|L|RULE OUT LIVER DISEASE, B12/FOLATENTE|3|L|DEFICIENCY, DRUG EFFECT, VIRAL DISEASE,NTE|4|L|IMMUNE DISEASE, ITPPID|3|||1005615461^QC^ON|MCLUHAN^MARSHALL||19110721|M|||||7055210038ORC|NW|ZL84676|||F|||||||273813^DR. K. S. TILBE|||20091002OBR|1|ZL84676||226^SODIUM||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|3210^SODIUM|CHEMISTRY^^|139|MMOL/L|135-146||||F||303^1003210||70OBR|2|ZL84676||204^POTASSIUM||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|3220^POTASSIUM|CHEMISTRY^^|3.6|MMOL/L|3.5-5.2||||F||303^1003220||70OBR|3|ZL84676||053^CHLORIDE||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|3230^CHLORIDE|CHEMISTRY^^|97|MMOL/L|95-108||||F||303^1003230||70OBR|4|ZL84676||329^FERRITIN||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|4050^FERRITIN|RIA^^|46|UG/L|27-220||||F||402^1004050||70OBR|5|ZL84676||393^COMPLETE BLOOD COUNT||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|2010^HEMOGLOBIN|HEMATOLOGY^^|145|G/L|135-180||||F||201^1002010||70OBX|2|ST|2013^HEMATOCRIT|HEMATOLOGY^^|0.432|L/L|0.37-0.54||||F||201^1002013||70OBX|3|ST|2016^WBC COUNT|HEMATOLOGY^^|8.2|X10 9/L|4.0-11.0||||F||201^1002016||70OBX|4|ST|2019^RBC COUNT|HEMATOLOGY^^|5.16|X10 12/L|4.50-6.50||||F||201^1002019||70OBX|5|ST|2022^MCV|HEMATOLOGY^^|83.6|FL|80-97||||F||201^1002022||70OBX|6|ST|2025^MCH|HEMATOLOGY^^|28.0|PG|27.0-32.0||||F||201^1002025||70OBX|7|ST|2028^MCHC|HEMATOLOGY^^|335|G/L|320-360||||F||201^1002028||70OBX|8|ST|2029^RDW|HEMATOLOGY^^|13.7|%|11.0-14.5||||F||201^1002029||70OBX|9|ST|2030^PLATELET COUNT|HEMATOLOGY^^|365|X10 9/L|150-400||||F||201^1002030||70OBX|10|ST|2191^ABSOLUTE:  NEUTROS|HEMATOLOGY^^|6.8|X10 9/L|2.0-7.5||||F||201^1002191||70OBX|11|ST|2193^     (A)   LYMPH|HEMATOLOGY^^|1.1|X10 9/L|1.1-3.3||||F||201^1002193||70OBX|12|ST|2196^     (A)   MONO|HEMATOLOGY^^|0.3|X10 9/L|0.0-0.8||||F||201^1002196||70OBX|13|ST|2197^     (A)   EOS|HEMATOLOGY^^|0.1|X10 9/L|0.0-0.5||||F||201^1002197||70OBX|14|ST|2198^     (A)   BASO|HEMATOLOGY^^|0.0|X10 9/L|0.0-0.2||||F||201^1002198||70OBR|6|ZL84676||451^SEDIMENTATION RATE||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|2113^ESR|HEMATOLOGY^^|42|MM/H|0-14|A|||F||230^1002113||70OBR|7|ZL84676||665HS^hs-CRP||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|2510^hs-CRP|HEMATOLOGY^^|29.6|MG/L||A|||F||270^1002510||70NTE|1|L|CUT POINTS FOR CARDIAC RISK ASSESSMENT ARE:NTE|2|L|LOW RISK LEVEL      <1.0 MG/LNTE|3|L|AVERAGE RISK LEVEL  1.0 - 3.0 MG/LNTE|4|L|HIGH RISK LEVEL     >3.0 MG/LNTE|5|L|VALUES >8.0 MG/L INDICATE INFLAMMATORYNTE|6|L|CONDITIONS AND MAY NOT PREDICT CARDIAC RISKNTE|7|L|.OBR|8|ZL84676||700^DOCUMENTATION FEE||20091002|20091002|||||||||273813^DR. K. S. TILBE|||||||||F|||290692^DR. NORMAN BETHUNEPID|4|||1006938243^XX^ON|BONDAR^ROBERTA||19451204|F|||||7055228824ORC|NW|ZL84708|||F|||||||290692^DR. NORMAN BETHUNE|||20091005OBR|1|ZL84708||066^CREATINE PHOSPHOKINASE||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3400^CK|CHEMISTRY^^|60|U/L|BELOW 170||||F||303^1003400||70OBR|2|ZL84708||223^SGPT (ALT)||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3380^ALT|CHEMISTRY^^|23|U/L|4-43||||F||303^1003380||70OBR|3|ZL84708||191^PHOSPHATASE ALKALINE||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3360^ALK PHOS|CHEMISTRY^^|65|U/L|30-110||||F||303^1003360||70OBR|4|ZL84708||030^BILRUBIN TOTAL||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3340^TOTAL BILIRUBIN|CHEMISTRY^^|13.0|UMOL/L|0.0-23.0||||F||303^1003340||70OBR|5|ZL84708||117^HDL/LDL||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|3120^CHOLESTEROL|CHEMISTRY^^|2.46|MMOL/L|TARGET <5.20||||F||365^1003120||70OBX|2|ST|3140^TRIGLYCERIDES|CHEMISTRY^^|1.36|MMOL/L|TARGET <1.71||||F||365^1003140||70OBX|3|ST|3923^HDL CHOLESTEROL|CHEMISTRY^^|0.92|MMOL/L|TARGET >1.29|A|||F||365^1003923||70OBX|4|ST|3933^LDL CHOLESTEROL|CHEMISTRY^^|0.92|MMOL/L|See Targets||||F||365^1003933||70OBX|5|ST|3939^CHOL/HDL RATIO|CHEMISTRY^^|2.67||See Targets||||F||365^1003939||70NTE|1|L|*----------*----------*----------*----------*NTE|2|L|Clinical Risk Status:  Target Lipid LevelsNTE|3|L|*----------*----------*----------*----------*NTE|4|L| If Risk  : LDL-C --Targets-- CHOL/HDL RatioNTE|5|L| Low      :  <5.1     and       <6.0NTE|6|L| Moderate :  <3.5     and       <5.0NTE|7|L| High     :  <2.0     and       <4.0NTE|8|L|...as per 2006 Canadian GuidelinesOBR|6|ZL84708||700^DOCUMENTATION FEE||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FPID|5|||6934959815^KV^ON|SMITH^ROBERT||19350208|M|||||7055220478ORC|NW|ZL84759|||F|||||||290692^DR. NORMAN BETHUNE|||20091005OBR|1|ZL84759||445^INR (PT)||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|2.2||0.8-1.2|A|||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|2|ZL84759||700^DOCUMENTATION FEE||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FPID|6|||6013740631^YW^ON|ERB^ROBERT||19380608|M|||||7055222209ORC|NW|ZL84763|||F|||||||290692^DR. NORMAN BETHUNE|||20091005OBR|1|ZL84763||445^INR (PT)||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|2.1||0.8-1.2|A|||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|2|ZL84763||700^DOCUMENTATION FEE||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FPID|7|||2342123052^CH^ON|PERREAULT^JEAN BAPTISTE||19280624|M|||||7056737602ORC|NW|ZL84771|||F|||||||290692^DR. NORMAN BETHUNE|||20091005OBR|1|ZL84771||445^INR (PT)||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|2.4||0.8-1.2|A|||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|2|ZL84771||700^DOCUMENTATION FEE||20091005|20091005|||||||||290692^DR. NORMAN BETHUNE|||||||||FPID|8|||1006938243^XX^ON|BONDAR^ROBERTA||19451204|F|||||7056757989ORC|NW|ZL84773|||F|||||||249581^DR. K. DEBLACAM|||20091005OBR|1|ZL84773||445^INR (PT)||20091005|20091005|||||||||249581^DR. K. DEBLACAM|||||||||F|||290692^DR. NORMAN BETHUNEOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|1.1||0.8-1.2||||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|2|ZL84773||700^DOCUMENTATION FEE||20091005|20091005|||||||||249581^DR. K. DEBLACAM|||||||||F|||290692^DR. NORMAN BETHUNEFTS|8